| Trial ID # | Retrospective Study: Hormonal Maintenance in LGSC |
| Phase | II |
| Drug Class | Hormonal Therapy: Aromatase, Hormonal Therapy: Aromatase |
| Drug Name | Anastrozole, Letrozole |
| Alternate Drug Names | Arimidex, Femara |
| Drugs in Trial | Anastrozole, Letrozole, Tamoxifen |
| Eligible Participant | Stage II-IV low grade serous ovarian cancer after surgery and first-line therapy |
| Patients Enrolled | 203 |
| Therapy Setting | Maintenance |
| Study Design | Open-Label, Non-randomized |
| Endpoints | PFS, OS, evaluated per RECIST or CA125 |
| Efficacy | Hormonal maintenance therapy (HMT)(n=70) vs routine observation (OBS)(n=133): PFS: 64.9 vs 26.4 months (p<0.001) |
| Conclusion | Significantly longer PFS with hormonal maintenance therapy (HMT) vs. observation in Low Grade Serous OC patients |
| Reference | Gershenson DM et al. Hormonal Maintenance Therapy for Women With Low-Grade Serous Cancer of the Ovary or Peritoneum. J Clin Oncol (2017) 35(10):1103-1111 |
Starting
January 1, 2025,
Clearity is joining
Ovarian Cancer
Research Alliance
(OCRA) and this website
will be redirected to
www.ocrahope.org
OCRA and Clearity are committed to serving the ovarian cancer community and providing the education, information, and support people need.